Cancer as an infectious disease: A different treatment alternative using a combination of tigecycline and pyrvinium pamoate - An example of breast cancer.

BACKGROUND: Tigecycline is an antibiotic that well tolerated for treating complicated infections. It has received attention as an anti-cancer agent and expected to solve two major obstacles, sides effects that accompany chemotherapy and drug resistance, in the breast cancer treatment. However, previous studies reported that the levels in the blood are typically low of tigecycline, so higher doses are needed to treat cancer, that may increase the risk of side effects. To achieve better anti-cancer effects for tigecycline, we need to find a novel adjunct agent. METHODS: In this study, we used different concentration of pyrvinium pamoate combined with tigecycline to treat cell. And assess the effect of two drugs in inhibit cell proliferation, induce cell autophagy, or increase cell apoptosis to evaluate the consequent of combined therapy. RESULTS: We observed that after the combined therapy, the cell cycle arrest at G1/s phase, the level of p21 increased, but decreased the levels of CDK2. Others, two drugs via different mechanisms to inhibit cancer cell proliferation and with selective cytotoxic to different cell lines. That could enhance the effect of breast cancer treatment. CONCLUSION: Combining low dose of tigecycline use with pyrvinium pamoate is a novel approach for breast cancer treatment. Appropriate combined therapy in breast cancer is recommended to improve outcomes. Other problems like drug resistance occur in patients or the microbes surrounding breast tissues would confer susceptibility to cancers then influence the effectiveness of treatment, which could be improved through combined therapy.

Brain-derived neurotrophic factor, adiponectin, and proinflammatory markers in various subtypes of depression in young men.

OBJECTIVES: We aimed to investigate levels of brain-derived neurotrophic factor (BDNF), adiponectin, and proinflammatory cytokines in various subtypes of depression in a cohort of young men. METHODS: Sixty-two men 18-30 years of age were recruited for the study. Forty-two were newly diagnosed with depression according to DSM-IV criteria and were divided into three subtypes: reactive depression (N = 13), major depression (N = 18), and bipolar depression (N = 10). Controls included 21 young men without significant clinical morbidity. Serum levels of BDNF, adiponectin, high sensitivity C-reactive protein (hsCRP), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) were measured. RESULTS: Serum BDNF was significantly lower and TNF-alpha significantly higher than controls for all subtypes of depression. No statistically significant differences between subtypes were found for BDNF, adiponectin, hsCRP, TNF-alpha, or IL-6. Although established diagnosis of depression and level of TNF-alpha were found to independently affect BDNF level in depressed subjects, they executed inverse effects. No associations were found between BDNF and adiponectin, hsCRP, TNF-alpha, or IL-6 in any depressed subject, showing that decreased BDNF in depression is influenced by multiple factors and complex mechanisms, including environmental and genetic concerns. No influence of age on BDNF level was found in any depressive subtype. CONCLUSIONS: Our results lend support to the cytokine and neurotrophic hypotheses of depression by demonstrating significantly lower levels of BDNF in all subtypes of depression. The mechanism underlying this phenomenon is uncertain and assumed to be multifactorial. Development of novel antidepressant treatments will require a multidisciplinary approach.

Baseline forced expiratory volume in the first second as an independent predictor of development of the metabolic syndrome.

A growing body of evidence strongly supports associations between reduced lung function and insulin resistance, type 2 diabetes mellitus, and cardiovascular disease. The present study was undertaken to explore the possibility that reduced lung function is an independent predictor of development of the metabolic syndrome (MetS) and to investigate potential links between reduced lung function and the MetS. A prospective cohort study of reduced lung function as a predictor of subsequent MetS was conducted using 2-year follow-up data for 450 middle-aged adults lacking the MetS at baseline. Data were obtained from the Taipei MJ Health Screening Centers in Taiwan. The MetS was defined according to the modified Adult Treatment Panel III criteria. Over 2 years of follow-up, 26 of the 450 subjects (5.78%) without the MetS at baseline subsequently developed the syndrome. In multiple logistic regression analysis with adjustments for age, sex, body mass index, cigarette smoking, alcohol consumption, and physical activities, reduced forced expiratory volume in the first second (FEV(1)) at baseline remained a predictor of subsequent MetS (relative risk of 4.644, P = .036 for the third [<2.31 L] vs first [>2.88 L] tertile). In Pearson and partial correlation analyses, white blood cell counts and C-reactive protein concentrations were both found to be significantly and negatively correlated with FEV(1). Lower FEV(1) is concluded to serve as an independent predictor of the MetS. Low-grade systemic inflammation is the possible link between reduced lung function and the MetS.